No Data
No Data
Talphera Reaches Agreement With FDA in Nephro CRRT Study
Express News | Talphera Announces Agreement With the FDA for Prior Approval Supplement Review to Reduce the Number of Patients in the Nephro Crrt Study
Talphera Announces Agreement With the FDA for Prior Approval Supplement Review to Reduce the Number of Patients in the NEPHRO CRRT Study
Express News | Talphera Inc - Receives Notice of Non-Compliance With Nasdaq Equity Requirement
Maxim Group Maintains Talphera(TLPH.US) With Buy Rating, Maintains Target Price $3
Talphera's Promising Prospects: Buy Rating Affirmed Amidst Strategic Advancements in Anticoagulant Development